IN Brief:
- Nourish Ingredients has completed a 10-tonne Creamilux campaign at SD Guthrie International Speciality Ingredients in the Netherlands.
- At an indicated inclusion rate around 0.2%, the batch could support roughly 5,000 tonnes of finished food.
- Further production increases towards 100 tonnes and 500 tonnes are intended to follow customer trials and confirmed orders.
Nourish Ingredients has completed a 10-tonne industrial production run of Creamilux at SD Guthrie International Speciality Ingredients’ facilities in the Netherlands, giving the company a substantially larger supply of its animal-free speciality lipid for customer trials and early commercial demand.
The campaign was completed using SD Guthrie’s existing industrial equipment rather than a purpose-built Nourish factory. The manufacturing partner will now act as Nourish Ingredients’ lead European production and scale-up partner for Creamilux, with output intended to increase as customer trials convert into orders.
Creamilux is designed to reproduce some of the mouthfeel and functionality associated with conventional dairy fats in applications including plant-based dairy, spreads, milk products, confectionery, bakery, and hybrid dairy formulations. Its manufacturing economics differ from a bulk fat because the ingredient is intended to work at a comparatively low inclusion rate.
Nourish Ingredients has indicated an inclusion level around 0.2% for some finished products. On that basis, the 10-tonne campaign could support roughly 5,000 tonnes of finished food, giving the company commercial trial volumes without requiring commodity-scale output of the ingredient itself.
That ratio changes the scale-up equation. A company producing a commodity oil, protein, or carbohydrate at high inclusion rates normally has to secure large annual tonnage before it can influence significant finished-product volumes; a more concentrated functional ingredient can reach the same volume of customer products from a much smaller manufacturing base.
The production arrangement also avoids one of the largest capital commitments facing emerging food-technology businesses. Rather than financing, building, commissioning, and staffing a dedicated plant, Nourish has transferred its process into an established speciality-lipid operation with existing manufacturing infrastructure and technical expertise.
European alternative-protein investment has increasingly concentrated on businesses reaching physical manufacturing milestones, with funding structures reflecting the high cost of process equipment, utilities, downstream operations, and the working capital required before plants reach stable utilisation.
Nourish is taking a different route. Its manufacturing partner already has the equipment and workforce, allowing the company to concentrate more of its capital on ingredient technology, customer qualification, and commercial development rather than carrying the cost of an underused factory while demand is still being established.
The industrial run has also provided a more demanding process test than pilot production. Nourish says Creamilux performed consistently across the campaign, giving the business confidence that the manufacturing process can be repeated at a scale large enough to supply global customers conducting formulation work.
Those trials will determine whether the production milestone becomes a durable manufacturing programme. Food companies assessing Creamilux will have to establish how the ingredient behaves in their own mixing, heating, emulsification, cooling, storage, and shelf-life conditions as well as whether its sensory performance justifies its cost.
Fat functionality is particularly difficult to replace through formulation alone. In dairy and plant-based foods, fats contribute lubrication, flavour release, creaminess, texture, and emulsion behaviour; in bakery and confectionery, they can also affect structure, melting profile, processing stability, and the finished eating experience.
Nourish says customer work is already under way across several of those applications, with the first products containing Creamilux expected to reach shelves within six months if current trials progress as planned. That timetable remains dependent on customer development programmes rather than manufacturing capacity alone.
The next production steps are being tied deliberately to demand. The company has discussed increases towards 100 tonnes, then 500 tonnes and beyond, but says the pace will be set by trials converting into commercial orders and offtake rather than by adding capacity in anticipation.
That approach is more cautious than the scale-up model seen across parts of food technology earlier in the decade, when large factories and ambitious nameplate capacities were sometimes announced well before equivalent customer demand had materialised. Underused specialist manufacturing capacity is expensive, even when the underlying technology works.
SD Guthrie’s infrastructure gives Nourish room to expand without taking that risk immediately. The manufacturing constraint has been reduced; the next constraint is customer adoption, repeat ordering, and the ability to reproduce ingredient performance across a growing number of commercial production campaigns.
The 10-tonne run therefore establishes industrial manufacturability, but it does not settle commercial scale. The harder measure will come from how quickly the material leaves trial formulations and reappears as repeat demand for the next 100 tonnes.
